| 價格 | ¥221 | ¥521 | ¥833 |
| 包裝 | 1mg | 5mg | 10mg |
| 最小起訂量 | 1mg |
| 發(fā)貨地 | 上海 |
| 更新日期 | 2026-04-02 |
| 中文名稱:化合物Exherin trifluoroacetate | 英文名稱:ADH-1 trifluoroacetate |
| CAS:1135237-88-5 | 品牌: TargetMol |
| 產(chǎn)地: 美國 | 保存條件: Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 純度規(guī)格: 98.00% | 產(chǎn)品類別: 抑制劑 |
| 貨號: T1608 |
| 名稱 | ADH-1 trifluoroacetate |
| 描述 | ADH-1 trifluoroacetate (Exherin trifluoroacetate) is a cyclic pentapeptide vascular-targeting agent with potential antineoplastic and antiangiogenic activities. ADH-1 selectively and competitively binds to and blocks N-cadherin, which may result in disruption of tumor vasculature, inhibition of tumor cell growth, and the induction of tumor cell and endothelial cell apoptosis. |
| 動物實驗 | Exherin is prepared in PBS.Animals are anesthetized, and 40 μL of a single cell suspension containing 50,000 cells is injected into the pancreas. Mice are randomized into treatment groups 10 days after surgery. For treatment, mice are injected intraperitoneally once per day with Exherin at 50 mg/kg in 100 μL PBS (×1 per day, ×5 per week for 4 weeks). For in vivo bioluminescence, D-Luciferin is administered by intraperitoneal injection. Data are acquired 20 min after injection using the IVIS system. Tumor growth is monitored every 10 days from day 10 to day 50 after surgery. Luciferase activity is quantified using the IVIS system. Two months after surgery, the mice are killed, and the pancreas, liver, lung, and disseminated nodules are harvested, fixed in 10% buffered formalin, and embedded in paraffin. Serial 5-μM sections are cut, mounted on slides, and stained with H&E using standard procedures. |
| 體外活性 | 在胰腺癌細胞中,Exherin (0.2 mg/mL) 阻斷了膠原蛋白I介導的變化且在阻止由N-cadherin表達引發(fā)的細胞移動性方面表現(xiàn)出高度效力。Exherin (0-1.0 mg/mL) 以N-cadherin依賴的方式劑量依賴性地誘導細胞凋亡。 |
| 體內(nèi)活性 | 在小鼠胰腺癌模型中,ADH-1 (50 mg/kg) 顯著抑制腫瘤生長和轉(zhuǎn)移[1]。在大鼠主動脈環(huán)實驗或PC3皮下異種移植瘤模型的抗腫瘤潛力評估中,ADH-1 未顯示出抗血管生成活性[2]。ADH-1 介導的黑色素瘤腫瘤生長增強作用不會因局部輸注替莫唑胺而改變。在A375異種移植瘤中,ADH-1 可增加AKT在絲氨酸473位點的磷酸化,但在DM443異種移植瘤中則無此效應。ADH-1 在兩種異種移植瘤中都略微降低N-鈣黏蛋白表達[3]。 |
| 存儲條件 | Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | DMSO : 43 mg/mL (62.8 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (2.92 mM), Sonication is recommended. |
| 關鍵字 | N-cadherin | Inhibitor | inhibit | Exherin Trifluoroacetate | ADH-1 Trifluoroacetate | ADH1 trifluoroacetate | ADH-1 | ADH1 | ADH 1 Trifluoroacetate | ADH 1 |
| 相關產(chǎn)品 | Lycorine hydrochloride | ML327 | Aristolactam I | Raludotatug | PTA001_A4 | MC-1-F2 | Cadherin Peptide, avian Acetate | PF-03732010 | ADH-1 | SD133 | BAS00093476 | RG-6125 |
| 相關庫 | 抑制劑庫 | 經(jīng)典已知活性庫 | 抗癌活性化合物庫 | 已知活性化合物庫 | 臨床失敗化合物庫 | 細胞凋亡化合物庫 | 多肽分子庫 | 藥物功能重定位化合物庫 | 抗代謝疾病化合物庫 | 抗癌臨床化合物庫 | 共價抑制劑庫 | 抗癌藥物庫 |
| 成立日期 | 2013-04-18 (14年) | 注冊資本 | 566.265100萬人民幣 |
| 員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
| 主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學,分子砌塊,生物技術服務 | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務 |
| 產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
|---|---|---|---|---|
| ¥1800 |
VIP7年
|
南昌探真生物技術有限公司
|
2026-05-09 | |
| 詢價 |
VIP5年
|
西安齊岳生物科技有限公司
|
2026-04-21 | |
| 詢價 |
VIP7年
|
南昌探真生物技術有限公司
|
2026-05-09 |